Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002493 · ClinicalTrials.gov registry record · Phase 3
Radiation Therapy Compared With Combination Chemotherapy in Treating Patients With Advanced Endometrial Cancer
A Phase 3 study of Endometrial Cancer and Psychosocial Effects of Cancer and Its Treatment, sponsored by Gynecologic Oncology Group.
- Completed
- Registry status
- Phase 3
- Development phase
- 20
- Study locations
NCT00002493 is a Phase 3 study of Endometrial Cancer and Psychosocial Effects of Cancer and Its Treatment that has completed, run by Gynecologic Oncology Group. The trial reports 20 study locations across 13 states.
The verdict
NCT00002493, a Phase 3 study of Endometrial Cancer and Psychosocial Effects of Cancer and Its Treatment, has completed, sponsored by Gynecologic Oncology Group.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 20
- Study locations
Study Summary
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known which treatment regimen is more effective for endometrial cancer. PURPOSE: Randomized phase III trial to compare radiation therapy with chemotherapy in treating patients who have advanced endometrial cancer.
Conditions Studied
Interventions
- DRUG cisplatin
- DRUG doxorubicin hydrochloride
- RADIATION low-LET photon therapy
Study Locations (20)
California
- USC/Norris Comprehensive Cancer Center - Los Angeles
- Jonsson Comprehensive Cancer Center, UCLA - Los Angeles
- Chao Family Comprehensive Cancer Center - Orange
- Women's Cancer Center - Palo Alto
- Stanford University Medical Center - Stanford
District of Columbia
- Vincent T. Lombardi Cancer Research Center, Georgetown University - Washington D.C.
- Walter Reed Army Medical Center - Washington D.C.
Georgia
- Emory University Hospital - Atlanta - Atlanta
- CCOP - Atlanta Regional - Atlanta
Illinois
- Rush-Presbyterian-St. Luke's Medical Center - Chicago
- University of Chicago Cancer Research Center - Chicago
Alabama
- University of Alabama Comprehensive Cancer Center - Birmingham
Arizona
- CCOP - Greater Phoenix - Phoenix
Colorado
- University of Colorado Cancer Center - Denver
Florida
- H. Lee Moffitt Cancer Center and Research Institute - Tampa
Trial Details
| Field | Value |
|---|---|
| Start Date | 1992-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00002493
The ClinicalTrials.gov registry entry for NCT00002493 describes a study currently listed as completed, categorized as Phase 3. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Gynecologic Oncology Group, which has 154 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Endometrial Cancer appearing as the primary indexed condition, and to 3 interventions - of which cisplatin is the first listed.
NCT00002493 reports 20 study locations spanning 13 distinct geographic areas - top geographies include California, District of Columbia, Georgia.
Frequently Asked Questions
What is clinical trial NCT00002493 about?
NCT00002493 is a clinical study titled "Radiation Therapy Compared With Combination Chemotherapy in Treating Patients With Advanced Endometrial Cancer". RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known which treatment regimen is more effective for endometrial cancer. PURPOSE: Randomized phase II...
What is the current status of trial NCT00002493?
This trial is currently completed. It is a Phase 3 study. The study started on 1992-05.
What conditions does trial NCT00002493 study?
This clinical trial studies the following conditions: Endometrial Cancer, Psychosocial Effects of Cancer and Its Treatment.
What interventions are being tested in trial NCT00002493?
The interventions under investigation include: cisplatin (DRUG), doxorubicin hydrochloride (DRUG), low-LET photon therapy (RADIATION).
Who is sponsoring clinical trial NCT00002493?
This trial is sponsored by Gynecologic Oncology Group, which has 154 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00002493 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Colorado, District of Columbia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Endometrial Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)
RECRUITING · Phase 3
-
Vaginal Cuff Brachytherapy Fractionation Study
RECRUITING · Phase 3
-
A Clinical Study of the Anti-cancer Effects of an Investigational Therapy or Chemotherapy in Patients With Recurring Uterine Cancer
RECRUITING · Phase 3
-
Study of Trastuzumab Deruxtecan Versus Standard of Care Chemotherapy for HER2-Expressing (IHC 3+/2+) Endometrial Cancer
RECRUITING · Phase 3
-
DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer
RECRUITING · Phase 3
-
Selinexor in Maintenance Therapy After Systemic Therapy for Participants With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma
RECRUITING · Phase 3
Explore more on PlainTrial
Endometrial Cancer
All registered trials for this condition
Psychosocial Effects of Cancer and Its Treatment
All registered trials for this condition
Alabama
All trials with a study site in Alabama
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.